Measurement of Beta Cell Death in Individuals With Cystic Fibrosis

Completed

Conditions studied: Cystic Fibrosis-related Diabetes

In brief

This study evaluates the feasibility of using differentially methylated insulin DNA, a biomarker of beta cell death, in determining the time course of beta cell death and development of diabetes in people with cystic fibrosis. Study participants with cystic fibrosis and healthy control participants will have a blood sample drawn in order to measure the levels of differentially methylated insulin DNA.

Key facts

Study ID

NCT03713437

Run by

University of Nebraska

People needed

40

Starts

2019-04-04

Expected to finish

2021-06-30

Last updated by the study team

2026-04-07

Who can join

Age: any, up to 21. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Children's Hospital and Medical Center — Omaha, Nebraska, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.